Spots Global Cancer Trial Database for pemetrexed
Every month we try and update this database with for pemetrexed cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | NCT03770299 | Non-Small Cell ... Non-Small-Cell ... Circulating Tum... | Nivolumab Vinorelbine Gemcitabine Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Observation | 18 Years - | Bristol-Myers Squibb | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | NCT05789082 | Non-Small Cell ... | Divarasib Pembrolizumab Carboplatin Cisplatin Pemetrexed | 18 Years - | Hoffmann-La Roche | |
| Alvopem® (Pemetrexed) Safety Assessment | NCT04843007 | Non Small Cell ... Malignant Pleur... | Pemetrexed | - | NanoAlvand | |
| Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers | NCT02296671 | Esophagogastric... | Pemetrexed Oxaliplatin Leucovorin Fluorouracil Germline genoty... | 18 Years - | Washington University School of Medicine | |
| Study of TRC102 in Combination With Pemetrexed in Cancer Patients | NCT00692159 | Neoplasm | TRC102 + pemetr... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned | NCT00191750 | Carcinoma, Smal... | Pemetrexed | 18 Years - | Eli Lilly and Company | |
| Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00071136 | Lung Neoplasms | pemetrexed gemcitabine | 18 Years - | Eli Lilly and Company | |
| Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas | NCT02120807 | Stage IV Lung A... | Certolizumab cisplatin pemetrexed | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | NCT03134872 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 Carboplatin Pemetrexed | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC | NCT03164694 | Lung Cancer | Apatinib Pemetrexed Carboplatin | 18 Years - 75 Years | Sun Yat-sen University | |
| Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | NCT03158129 | Stage I Lung No... Stage IA Lung N... Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Carboplatin Cisplatin Docetaxel Ipilimumab Nivolumab Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer | NCT01860040 | Non-squamous Ce... Squamous Cell N... | Cisplatin Pemetrexed Gemcitabine | 18 Years - | Western Regional Medical Center | |
| Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations | NCT00891579 | Non Small Cell ... | Pemetrexed (Ali... Gefitinib (IRES... | 18 Years - 80 Years | Chinese Society of Lung Cancer | |
| Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma | NCT00190801 | Gastrointestina... | pemetrexed cisplatin | 18 Years - 70 Years | Eli Lilly and Company | |
| A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) | NCT04153565 | Mesothelioma | Pembrolizumab Pemetrexed Cisplatin | 20 Years - | Merck Sharp & Dohme LLC | |
| Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192 | Ovarian Carcino... Primary Periton... | Pemetrexed Bevacizumab | 18 Years - | Washington University School of Medicine | |
| Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | NCT04220892 | High Grade Glio... | Pembrolizumab Pemetrexed Abemaciclib | 18 Years - | Saint John's Cancer Institute | |
| Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer | NCT04683965 | Colorectal Neop... | Pemetrexed TAS-102 Bevacizumab | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed | NCT00497770 | Lung Neoplasms | Pemetrexed | 18 Years - | Eli Lilly and Company | |
| Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection | NCT04762459 | Non-small Cell ... | Almonertinib Pemetrexed Cisplatin | 18 Years - 130 Years | ChineseAMS | |
| BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | NCT00949650 | Carcinoma, Non-... Adenocarcinoma | Pemetrexed BIBW 2992 Cisplatin | 18 Years - | Boehringer Ingelheim | |
| Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy | NCT00109096 | Ovarian Neoplas... Primary Periton... | Pemetrexed | 18 Years - | Eli Lilly and Company | |
| Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | NCT04367311 | Lung Cancer NSCLC | Atezolizumab Docetaxel Cisplatin Pemetrexed | 18 Years - | Big Ten Cancer Research Consortium | |
| Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC | NCT03607539 | Lung Neoplasms | Sintilimab Pemetrexed Platinum Placebos | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00265785 | Lung Cancer | pemetrexed | 18 Years - | SWOG Cancer Research Network | |
| Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer | NCT02609776 | Non-Small-Cell ... | Amivantamab Amivantamab Lazertinib Carboplatin Pemetrexed | 18 Years - | Janssen Research & Development, LLC | |
| Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer | NCT01481259 | Non-small Cell ... | Autologous cyto... Pemetrexed | 18 Years - 75 Years | People's Hospital of Guangxi | |
| Pemetrexed in Patients With Soft Tissue Sarcoma | NCT00427466 | Sarcoma | Pemetrexed | 18 Years - 90 Years | University Hospital Tuebingen | |
| Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib | NCT02604342 | Non-small Cell ... | Alectinib Docetaxel Pemetrexed | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02367781 | Carcinoma, Non-... | Atezolizumab (M... Carboplatin Nab-Paclitaxel Pemetrexed | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC | NCT05583188 | NSCLC | Aliya Pulsed El... Nivolumab plus ... Standard of car... Surgical Resect... | 18 Years - | Galvanize Therapeutics, Inc. | |
| A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | NCT02259582 | Nonsquamous Non... | Pemetrexed Carboplatin demcizumab | 21 Years - | Mereo BioPharma | |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | NCT03134872 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron... | SHR-1210 Carboplatin Pemetrexed | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma | NCT00738582 | Malignant Pleur... | MORAb-009 (Amat... Pemetrexed Cisplatin | 18 Years - | Morphotek | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium | NCT00035061 | Urologic Neopla... Metastases, Neo... | pemetrexed | 18 Years - | Eli Lilly and Company | |
| A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801) | NCT00886678 | Non-Small Cell ... | pemetrexed carboplatin thoracic radiat... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Phase 2 Trial of Bevacizumab in Combination With Pemetrexed | NCT00227019 | Non-small Cell ... Lung Cancer Neoplasm Metast... | Bevacizumab Pemetrexed Vitamin B12 Folate Dexamethasone | 18 Years - | Stanford University | |
| Maintaining ERBB Blockade in EGFR-mutated Lung Cancer | NCT02488694 | Non-small-cell ... | Afatinib Pemetrexed | 18 Years - | AIO-Studien-gGmbH | |
| A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | NCT00297089 | Lung Cancer NSCLC Non-Small-Cell ... | ABT-751 pemetrexed placebo | 18 Years - | AbbVie | |
| A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | NCT03215706 | Non-Small Cell ... | Ipilimumab Nivolumab Carboplatin Paclitaxel Pemetrexed Cisplatin | 18 Years - | Bristol-Myers Squibb | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment | NCT00807573 | Lung Cancer | Paclitaxel Pemetrexed Bevacizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants | NCT05136677 | Mesothelioma, M... | Nivolumab Ipilimumab Pemetrexed Cisplatin Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer | NCT00190840 | Carcinoma, Non-... | pemetrexed | 18 Years - | Eli Lilly and Company | |
| Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | NCT01918761 | Non Small Cell ... | Dacomitinib, Pe... | 18 Years - | Central European Cooperative Oncology Group | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC | NCT02337530 | Non-Small Cell ... | Selumetinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Canadian Cancer Trials Group | |
| Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | NCT03987867 | Non-small Cell ... First-line Trea... | CIK cell Sintilimab Inje... Pemetrexed Liposome paclit... Carboplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer | NCT04736173 | Non Small Cell ... Nonsquamous Non... Squamous Non Sm... Lung Cancer | Domvanalimab Zimberelimab Carboplatin Paclitaxel Pemetrexed Pembrolizumab | 18 Years - | Arcus Biosciences, Inc. | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | NCT05012254 | Non Small Cell ... Brain Metastase... Lung Cancer | Ipilimumab Nivolumab Carboplatin Cisplatin Paclitaxel Pemetrexed | 18 Years - | Fundación GECP | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer | NCT01860040 | Non-squamous Ce... Squamous Cell N... | Cisplatin Pemetrexed Gemcitabine | 18 Years - | Western Regional Medical Center | |
| A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | NCT02864251 | Non-Small-Cell ... | Nivolumab Ipilimumab Pemetrexed Cisplatin Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | NCT05766800 | Locally Advance... Non-small Cell ... | Serplulimab Carboplatin Pemetrexed Nab-paclitaxel Liposomal pacli... Surgery Radiotherapy | 18 Years - | Shanghai Pulmonary Hospital, Shanghai, China | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer | NCT00102219 | Breast Cancer | Pemetrexed Doxorubicin | 18 Years - | Eli Lilly and Company | |
| Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC | NCT01742767 | NSCLC | Cisplatinum Pemetrexed | 18 Years - 75 Years | Universität Duisburg-Essen | |
| A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer | NCT05104788 | Non-Small Cell ... | Icotinib Cisplatin Carboplatin Pemetrexed | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer | NCT03432598 | Locally Advance... | Tislelizumab Paclitaxel Gemcitabine Etoposide Pemetrexed Cisplatin Carboplatin | 18 Years - 75 Years | BeiGene | |
| Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | NCT05258279 | Non-squamous No... EGFR Activating... | Pembrolizumab Lenvatinib Carboplatin Pemetrexed | 20 Years - | Juntendo University | |
| A Trial for Patients With Advanced/Recurrent Cervical Cancer | NCT00190983 | Cervical Intrae... Uterine Neoplas... Genital Neoplas... | Pemetrexed | - | Eli Lilly and Company | |
| Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC | NCT03790228 | Non-squamous Ce... | Anlotinib Combi... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors | NCT02921984 | Salivary Gland ... Head and Neck C... | Docetaxel Intensity-modul... Pemetrexed Cisplatin | 18 Years - 70 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy | NCT03086538 | Colo-rectal Can... | Pemetrexed Tarceva 100Mg T... | 20 Years - | Samsung Medical Center | |
| AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer | NCT00961415 | Non-Squamous No... | bevacizumab [Av... cisplatin pemetrexed | 18 Years - | Hoffmann-La Roche | |
| Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer | NCT00095199 | Non Small Cell ... | Pemetrexed Cetuximab Docetaxel | 18 Years - | Eli Lilly and Company | |
| A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy | NCT00447421 | Small Cell Lung... Carcinoma, Smal... SCLC | pemetrexed cisplatin radiation | 18 Years - | Eli Lilly and Company | |
| AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen | NCT00372788 | Non-small Cell ... | AZD6244 Pemetrexed | 18 Years - | AstraZeneca | |
| TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV | NCT01674738 | Carcinoma, Non-... | Pemetrexed Cisplatin Bevacizumab | 18 Years - 70 Years | Aktion Bronchialkarzinom e.V. | |
| An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | NCT05112965 | Neoplasms | Atezolizumab Bevacizumab Pemetrexed Paclitaxel Enzalutamide | 18 Years - | Hoffmann-La Roche | |
| Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | NCT04956692 | Non-Small Cell ... | Pembrolizumab S... Pembrolizumab I... Paclitaxel Nab-Paclitaxel Carboplatin Cisplatin Pemetrexed | 18 Years - | Merck Sharp & Dohme LLC | |
| JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | NCT05664971 | Advanced Lung C... | Recombinant hum... Toripalimab Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Etoposide | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| KN046 in Patients With Advanced Non-small Cell Lung Cancer | NCT03838848 | Stage IV Non-sm... | KN046 KN046 KN046 Carboplatin Pemetrexed Ningetinib | 18 Years - 75 Years | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis | NCT05305885 | Leptomeningeal ... | Pemetrexed Radiotherapy | 18 Years - 75 Years | The First Hospital of Jilin University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
